News

Sorted by: Date | Title

“Stapled” antimicrobial peptides could combat antibiotic resistance

August 19, 2019
The peptides, folded into specific three-dimensional shapes using chemical “staples” for reinforcement, kill multidrug resistant bacteria but don’t harm red blood cells or other normal tissues.

Leonard Zon, MD, honored by the American Society of Hematology for Outstanding Mentorship

July 18, 2019
The ASH Mentor Award recognizes hematologists who have excelled in mentoring trainees and colleagues.

Dana-Farber/Boston Children's nation’s #1 pediatric cancer program

June 18, 2019
U.S. News & World Report has named Dana-Farber/Boston Children’s Cancer and Blood Disorders Center the nation’s #1 pediatric cancer program in its new 2019-20 Best Children’s Hospitals rankings.

Katherine E. Warren, MD, joins Dana-Farber/Boston Children’s as Clinical Director for Pediatric Neuro-Oncology

June 04, 2019
Warren is an internationally recognized expert in pediatric neuro-oncology. Her work focuses on rational, pharmacokinetic-based drug development for children with brain tumors, and she is a leading innovator in developing new means of drug delivery.

Lynda M. Vrooman to present findings from Dana-Farber/Boston Children’s clinical trial that led to FDA approval of novel drug for treatment of ALL in young patients

May 23, 2019
Vrooman will share the abstract at the 2019 Annual Meeting of the American Society of Clinical Oncology (ASCO).

Team led by Dana-Farber/Boston Children’s Kimberly Stegmaier receives SU2C Sharp Award from Stand Up To Cancer

May 15, 2019
Stand Up To Cancer (SU2C) announced on May 2 that a team led by Kimberly Stegmaier, MD, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, and Sarah Tasian, MD, Children's Hospital of Philadelphia, was awarded a two-year grant totaling $250,000. Their SU2C Sharp Award is titled: Precision combinatorial immunotherapeutic targeting of thymic stromal lymphopoietin receptor (TSLPR) signaling in pediatric and young adult CRLF2-rearranged ALL.

Researchers at Dana-Farber/Boston Children's and UMass Medical School optimize gene editing for sickle cell disease and beta thalassemia

March 28, 2019
Researchers at Dana-Farber/Boston Children's Cancer and Blood Disorders Center and the University of Massachusetts Medical School have developed a strategy to treat two of the most common inherited blood diseases, sickle cell disease and beta thalassemia, applying CRISPR-Cas9 gene editing to patients' own blood stem cells.

Scott Armstrong, MD, PhD, recognized by ISSCR for contributions to basic and translational research in hematological disorders

March 25, 2019
The International Society for Stem Cell Research (ISSCR) announced that Scott Armstrong, MD, PhD, is the recipient of its 2019 Tobias Award Lecture.

Dana-Farber/Boston Children's Brian D. Crompton, MD, awarded research grant by the Go4theGoal Foundation

March 25, 2019
The Go4theGoal Foundation (G4TG) recently awarded Brian Crompton, MD, of the Dana-Farber/Boston Children's Cancer and Blood Disorders Center, a $50,000 research grant.
Showing 1-10 of 12 items